Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 136 of the 144 references it cites were found in a registry or an index; 187 of the 232 sources its claims cite were checked for support.

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance

Open access

Abstract

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRAS, including small molecule compounds targeting specific KRAS mutations, pan-KRAS inhibitors, PROTACs, siRNAs, PNAs, and mutant KRAS-specific immunostimulatory strategies. A central challenge to therapeutic effectiveness is the frequent development of resistance to these treatments. Direct resistance mechanisms can involve KRAS mutations that reduce drug efficacy or copy number alterations that increase the expression of mutant KRAS. Indirect resistance mechanisms arise from mutations that can rescue mutant KRAS-dependent cells either by reactivating the same signaling or via alternative pathways. Further, non-mutational forms of resistance can take the form of epigenetic marks, transcriptional reprogramming, or alterations within the tumor microenvironment. As the possible strategies to inhibit KRAS expand, understanding the nuances of resistance mechanisms is paramount to the development of both enhanced therapeutics and innovative drug combinations.

Overview

CoChat Summary

TL;DR

This review summarizes KRAS biology, the main classes of KRAS-targeted therapies, and the many ways tumors evade them. It emphasizes that resistance is common after KRAS inhibition and that combination strategies and new drug modalities are needed to improve durability.

Key findings

  • KRAS mutations are reported in 25–30% of all human cancers, including about 19% of NSCLCs, 40% of CRCs, and 73% of PDAC cases.
  • For KRAS G12C inhibitors, clinical benefit is limited by relapse: in NSCLC, median response durations were in the 6–7 month range before resistance emerged.
  • In a sotorasib-treated patient study, 7% developed KRAS G12C amplifications; in post-sotorasib tumors, 14% had an additional or alternative KRAS point mutation.
  • Multiple inhibitor classes are discussed as active or promising, including sotorasib and adagrasib for G12C, MRTX1133 for G12D, BI-2865 as a pan-KRAS inhibitor, and RMC-6291 as a CYPA-recruiting strategy; several are noted as being in clinical trials.

Methods

  • The paper is a narrative review of KRAS biology, therapeutic strategies, and resistance mechanisms.
  • It synthesizes evidence from preclinical models (cell lines, mouse models, xenografts, PDXs) and clinical studies/trials of KRAS-targeted agents.
  • The main analysis is a mechanism-based synthesis organized into KRAS regulation, inhibitor classes, immunotherapies, and mutational/non-mutational resistance pathways.

Limitations

  • The paper does not present a new primary dataset or perform a formal meta-analysis; this is evident from the text.
  • It notes that many strategies remain preclinical or in ongoing clinical trials, so clinical effectiveness is not yet established; this is stated in the paper.
  • The text makes evident that several conclusions are based on heterogeneous models (cell lines, murine xenografts, patient samples, and basket trials), which limits direct comparability across findings; this is evident from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/curroncol31040150

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (a) Domain architecture of KRAS; (b) frequency of KRAS mutation by disease and location. Specific amino acid changes at G12 are color-coded by relative frequency. Mutation data were downloaded from the curated set of non-redundant samples in cBioportal [1,2]. NSCLC, non-small cell lung cancer; CRC, colorectal carcinoma; PDAC, pancreatic ductal adenocarcinoma; aa, amino acid. (c) Pie charts showing the frequency of KRAS mutations in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. G12 mutations are color-coded as in (b). The other category represents KRAS mutations that are not G12C, G12D, G12R, G12V, or G12S.
Figure 1 (a) Domain architecture of KRAS; (b) frequency of KRAS mutation by disease and location. Specific amino acid changes at G12 are color-coded by relative frequency. Mutation data were downloaded from the curated set of non-redundant samples in cBioportal [1,2]. NSCLC, non-small cell lung cancer; CRC, colorectal carcinoma; PDAC, pancreatic ductal adenocarcinoma; aa, amino acid. (c) Pie charts showing the frequency of KRAS mutations in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. G12 mutations are color-coded as in (b). The other category represents KRAS mutations that are not G12C, G12D, G12R, G12V, or G12S.CC BY · PubMed Central
Figure 2 Diagram of signaling pathways related to KRAS. Growth signals stimulate KRAS to enter the active GTP-bound state. Downstream pathways, including PI3K and RAF proteins, translate active KRAS into signals for proliferation and survival. See the Glossary for acronym definitions.
Figure 2 Diagram of signaling pathways related to KRAS. Growth signals stimulate KRAS to enter the active GTP-bound state. Downstream pathways, including PI3K and RAF proteins, translate active KRAS into signals for proliferation and survival. See the Glossary for acronym definitions.CC BY · PubMed Central
Figure 3 Schematic of categories of KRAS-focused strategies for inhibiting KRAS-mutant cancers. KRAS can be inhibited at the level of DNA, mRNA, protein, or as an antigen targeting the cell for immune destruction. Inhibitor strategies are shown in red. The red star represents an activating point mutation in KRAS. On the MHC, the red star represents an antigen containing a KRAS-mutant fragment. See the Glossary for acronym definitions.
Figure 3 Schematic of categories of KRAS-focused strategies for inhibiting KRAS-mutant cancers. KRAS can be inhibited at the level of DNA, mRNA, protein, or as an antigen targeting the cell for immune destruction. Inhibitor strategies are shown in red. The red star represents an activating point mutation in KRAS. On the MHC, the red star represents an antigen containing a KRAS-mutant fragment. See the Glossary for acronym definitions.CC BY · PubMed Central
Figure 4 Model of RAS survival signals in wildtype and mutant KRAS cells. (a) In wildtype cells, KRAS, NRAS, and HRAS have overlapping functions regulating RAF activation. A pan-KRAS inhibitor may be tolerated because NRAS and HRAS can maintain normal survival signals. (b) KRAS-mutant cancer cells are rewired to be dependent on their continuous expression. The sudden inhibition of mutant KRAS rapidly decreases proliferation and survival signals, represented by red Xs. See the Glossary for acronym definitions.
Figure 4 Model of RAS survival signals in wildtype and mutant KRAS cells. (a) In wildtype cells, KRAS, NRAS, and HRAS have overlapping functions regulating RAF activation. A pan-KRAS inhibitor may be tolerated because NRAS and HRAS can maintain normal survival signals. (b) KRAS-mutant cancer cells are rewired to be dependent on their continuous expression. The sudden inhibition of mutant KRAS rapidly decreases proliferation and survival signals, represented by red Xs. See the Glossary for acronym definitions.CC BY · PubMed Central

Verification

Claims the paper makes

132 Valid · 9 Not valid · 25 Not checked · 30 Own results and interpretations

123 more claims · 89 with their cited sources checked

Create a free account to see all 196 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 15
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Citations

Cites

Show all 144 references

Research works printed but not linked: 1

  1. Weinberg, R.A. (2014). The Biology of Cancer, Garland Science, Taylor & Francis Group, LLC. [2nd ed.].

Cited by

See all 68

Metadata

Authors
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L.
Affiliations
  • The Graduate Center, CUNY (US)
  • City University of New York (US)
Corresponding author
Wolfe, Andrew L.
Venue
Current Oncology
Publisher
MDPI AG
Published
2024-04-03
Volume
31
Issue
4
Pages
2024-2046
ISSN
  • 1198-0052 (ISSN-L)
  • 1718-7729
OpenAlex
W4393869729
Cited by
68
References
144
Citations by year
2026: 39 · 2025: 23 · 2024: 6
FWCI
2.52
Type
journal article
Language
en
Open access
Locations
  • Current Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Cancer Institute (R00CA226363, DRG2214-15)
  • Hunter College of the City University of New York (R00CA226363, DRG2214-15)
  • Oncogenuity, Inc. (R00CA226363, DRG2214-15)
  • Damon Runyon Cancer Research Foundation (R00CA226363, DRG2214-15)
  • Graduate Center of the City University of New York (R00CA226363, DRG2214-15)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS, small GTPases, oncogenic KRAS mutations, KRAS inhibitors, drug resistance mechanisms, pan-KRAS inhibitors, PROTACs, siRNA, peptide nucleic acid, copy number alterations, alternative signaling pathways, epigenetic resistance, tumor microenvironment, cancer therapy
MeSH terms
Antineoplastic Agents, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance. https://app.cochat.ai/papers/10.3390/curroncol31040150
The paper
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024). KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance. Current Oncology. https://doi.org/10.3390/curroncol31040150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.